Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables (2016 - 2023)

Ocular Therapeutix has reported Notes Payables over the past 9 years, most recently at $2.1 million for Q2 2023.

  • Quarterly results put Notes Payables at $2.1 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $2.1 million (changed N/A YoY), and the annual figure for FY2020 was $8.3 million, changed.
  • Notes Payables for Q2 2023 was $2.1 million at Ocular Therapeutix, down from $8.3 million in the prior quarter.
  • Over the last five years, Notes Payables for OCUL hit a ceiling of $8.3 million in Q4 2020 and a floor of $2.1 million in Q1 2020.
  • Median Notes Payables over the past 3 years was $5.2 million (2020), compared with a mean of $5.2 million.
  • Peak annual rise in Notes Payables hit 299.71% in 2021, while the deepest fall reached 299.71% in 2021.
  • Ocular Therapeutix's Notes Payables stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then tumbled by 74.87% to $2.1 million in 2023.
  • The last three reported values for Notes Payables were $2.1 million (Q2 2023), $8.3 million (Q1 2021), and $8.3 million (Q4 2020) per Business Quant data.